Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 126 participants.

Also called NCT02021409

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 126 participants (enrolled count) (from the registry)
Sponsor
  • Bayer Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02021409
  • EudraCT 2013-001192-21
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Australia, Bulgaria, France, Germany, Hungary, Israel, Italy, Japan, Poland, Romania, South Korea, Spain, Türkiye, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02021409. Randomized; no masking; primary purpose treatment. Start 2014-01-28 (actual); primary completion 2015-10-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Maintenance Treatment of Anemia in Pre-dialysis Subjects With Chronic Kidney Disease on Darbepoetin Treatment Versus BAY85-3934
Acronym
DIALOGUE 2
Condition
Anemia
Condition
Renal Insufficiency, Chronic
Intervention (Drug)
BAY85-3934
Intervention (Biological)
Darbepoetin alfa
Lead sponsor
Bayer (class: industry)

Record details

Record id
cardio:ct-nct02021409
Content hash
2bcb7ffa3da73175f0643583615d6c09a90880db39271d6adcee244bc0b7211f